|
O'Connor, Owen A; Portlock, Carol; Moskowitz, Craig et al. (2010) Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 16:719-26
|
|
Gerecitano, John; Portlock, Carol; Moskowitz, Craig et al. (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146:652-5
|
|
O'Connor, Owen A; Moskowitz, Craig; Portlock, Carol et al. (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas Br J Haematol 145:34-9
|
|
O'Connor, Owen A; Portlock, Carol; Moskowitz, Craig et al. (2008) A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 143:201-9
|
|
Stubblefield, M D; Slovin, S; MacGregor-Cortelli, B et al. (2006) An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18:410-8
|
|
Paoluzzi, Luca; O'Connor, Owen A (2006) Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 20:13-23
|
|
Gerecitano, John; Goy, Andre; Wright, John et al. (2006) Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 134:391-8
|
|
Su, Yungpo Bernard; Vickers, Andrew J; Zelefsky, Michael J et al. (2006) Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J 12:182-8
|
|
O'Connor, Owen A (2005) Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl :150-8
|
|
O'Connor, Owen A (2005) Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 6:191-9
|
Showing the most recent 10 out of 16 publications
